Completed OBSERVATIONAL NCT01078246

Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)

Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network

Sponsor: Kaiser Permanente

Updated 12 times since 2017 Last updated: Jul 24, 2018 Started: Aug 31, 2009 Primary completion: Dec 9, 2014 Completion: Dec 9, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on HIV-1 Infections, this trial is completed. The trial is conducted by Kaiser Permanente and has accumulated 12 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed
Dec 2022 — Jan 2023 [monthly]

Completed
Jun 2022 — Dec 2022 [monthly]

Completed

▶ Show 7 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed
Sep 2018 — Jan 2021 [monthly]

Completed
Jun 2018 — Sep 2018 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Feb 2017 — Aug 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kaiser Permanente
Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.